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Background: Airway smooth muscle (ASM) remodeling is an important component
of the structural changes to airways seen in asthma. Eosinophils are the prominent
inflammatory cells in asthma, and there is some evidence that they contribute to
ASM remodeling via released mediators and direct contact through integrin–ligand
interactions. Eosinophils express several types of outer membrane integrin, which are
responsible for cell–cell and cell–extracellular matrix interactions. In our previous study
we demonstrated that asthmatic eosinophils show increased adhesion to ASM cells and
it may be important factor contributing to ASM remodeling in asthma. According to these
findings, in the present study we investigated the effects of suppression of eosinophil
integrin on eosinophil-induced ASM remodeling in asthma.
Materials andMethods: Individual combined cell cultures of immortalized human ASM
cells and eosinophils from peripheral blood of 22 asthmatic patients and 17 healthy
controls were prepared. Eosinophil adhesion was evaluated using eosinophil peroxidase
activity assay. Genes expression levels in ASM cells and eosinophils were measured
using quantitative real-time PCR. ASM cell proliferation wasmeasured using alamarBlue®
solution. Eosinophil integrins were blocked by incubating with Arg-Gly-Asp-Ser peptide.
Results: Eosinophils from the asthma group showed increased outer membrane α4β1
and αMβ2 integrin expression, increased adhesion to ASM cells, and overexpression
of TGF-β1 compared with eosinophils from the healthy control group. Blockade of
eosinophil RGD-binding integrins by Arg-Gly-Asp-Ser peptide significantly reduced
adhesion of eosinophils to ASM cells in both groups. Integrin-blocking decreased
the effects of eosinophils on TGF-β1, WNT-5a, and extracellular matrix protein gene
expression in ASM cells and ASM cell proliferation in both groups. These effects were
more pronounced in the asthma group compared with the control group.
Conclusion: Suppression of eosinophil-ASM interaction via RGD-binding integrins
attenuates eosinophil-induced ASM remodeling in asthma.
Trial Registration: ClinicalTrials.gov Identifier: NCT02648074.
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INTRODUCTION
Asthma is a heterogeneous disease with imbalanced airway
tissue repair associated with airway inflammation that is rich
in eosinophils (Scott and Wardlaw, 2006; Blanchard and
Rothenberg, 2009). With asthma, structural changes in the
airways, called airway remodeling, includes subepithelial fibrosis,
increased smooth muscle mass (Holgate, 2000; Halayko et al.,
2006), enlargement of glands, neovascularization (Tanaka et al.,
2003), and epithelial alterations (Bousquet et al., 2000). An
important determinant of airflow limitation in asthma is the
degree of airway smooth muscle (ASM) remodeling, which is
not a well-studied factor in the pathophysiology of asthma. It
includes ASM thickening that is a result from increased ASM cells
proliferation and extracellular matrix (ECM) proteins expression
(Dekkers et al., 2009). Pathobiological mechanisms for airway
remodeling are not fully elucidated, but there appears to be a
direct correlation with chronic inflammatory conditions in the
airways (Fajt and Wenzel, 2015).
In asthmatic lungs there is increased abundance of growth
factors and inflammatory mediators that can directly stimulate
the multifunctional behavior of ASM cells (Ngoc et al.,
2005). A primary source of cytokines, chemokines and growth
factors released in the lungs are inflammatory cells, including
eosinophils (Cheung et al., 2008). However, there is not a robust
body of evidence that clarifies the details of how inflammatory
cells contribute to ASM remodeling. Eosinophil infiltration in
the bronchial mucosa is controled by various cytokines and
chemokines, such as interleukin (IL) -5, -13 the eotaxins,
RANTES, and involves signaling via Rho-kinase (Chiappara
et al., 2001; Taki et al., 2007; Murdoch and Lloyd, 2010; Possa
et al., 2012). Activated by IL-5 family cytokines, eosinophils
are significant source of transforming growth factor-β1 (TGF-
β1) which can induce hypertrophic and hyperplastic ASM cell
growth (Chen and Khalil, 2006; Xiao et al., 2012). TGF-β1 is
a key mediator involved in tissue remodeling in the asthmatic
lung and eosinophils are the main cell type that produce this
profibrotic cytokine in asthma. Many studies have reported
increased levels of TGF-β1 in asthmatic patients, but the main
mechanisms behind this increase remain unclear. TGF-β1 has
the ability to induce a transformational change in normal cells
that effects a number of cellular biological processes as epithelial
changes, subepithelial fibrosis andmicrovascular changes leading
to airway remodeling (Halwani et al., 2011). Moreover TGF-
β1 can promote ECM protein biosynthesis via canonical Smad-
signaling (Sethi et al., 2011) as well as non-canonical WNT
signaling (Kumawat et al., 2013). Non-canonical Wnt signaling
can contribute to ASM remodeling via ECM protein production
(Kumawat et al., 2013). Altered structural function of type-1
Abbreviations: ASM, airway smooth muscle; ECM, extracellular matrix; TGF-β1,
transforming growth factor-β1; Wnt, wingless/integrase-1 signaling; Wnt-
5a, non-canonical Wnt signaling pathway activating ligand 5a; WNT-5a,
gene coding Wnt-5a ligand; PCR, polymerase chain reaction; EDTA,
ethylenediaminetetraacetic acid; PBS, phosphate-buffered saline; EPO,
eosinophil peroxidase; ELISA, enzyme-linked immunosorbent assay; EDTA,
ethylenediaminetetraacetic acid; DMEM, Dulbecco’s modified eagle medium;
ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion
molecule-1; FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; DTT, dithiothreitol.
collagen and the amount of fibronectin can act not only as a
proliferative signal for structural cells but can also play a part in
increasing ASMmass in asthma (Johnson et al., 2004).
There is evidence that eosinophils contribute to ASM
remodeling through direct contact via integrin-ligand
interaction (Hughes et al., 2000). Integrins are dimeric
transmembrane receptors that are the link for cell–cell and
cell–ECM interactions. Cell adhesion through integrins can
trigger a signal transduction that controls cells growth, division,
survival, cellular differentiation, and apoptosis (Kim et al., 2011;
Carbonell et al., 2013). Seven integrin heterodimers expressed
by eosinophils (α4β1, α6β1, αLβ2, αMβ2, αXβ2, αDβ2, and
α4β7) mediate diverse functions, including eosinophil rolling,
stable adhesion, migration, respiratory bursts, degranulation,
and viability after interaction with ligands including adhesion
molecules, laminin, fibrinogen/fibrin, vitronectin, and periostin
on other cells or in the ECM (Barthel et al., 2008; Johansson
and Mosher, 2013; Johansson et al., 2013). ASM cells express
VCAM-1 and ICAM-1 adhesion molecules, which can act as
ligands for eosinophils integrins α4β1 and αMβ2 and previous
study revealed that the adhesion ability of eosinophils in asthma
patients is significantly greater than the adhesion ability of
eosinophils from healthy people (Januskevicius et al., 2016).
On this basis, the potential that blocking eosinophil surface
integrins as a means to suppress the impact of inflammation on
airway structural cells and airway remodeling, has emerged as a
potential therapeutic approach for asthma (Dekkers et al., 2010).
We previously demonstrated that asthmatic eosinophils
significantly enhance ASM cells proliferation comparing with
healthy eosinophils and it may be related with increased
eosinophils adhesion and their effect on TGF-β1, WNT-5a and
ECM proteins production (Januskevicius et al., 2016). These
findings led us to investigate possible ways how to prevent
eosinophils effects on ASM remodeling in asthma. There are
few suppressing agents targeting eosinophil activity that can be
used in vitro to control eosinophil-induced ASM remodeling.
We tested the hypothesis that using the small tetrapeptide Arg-
Gly-Asp-Ser (RGDS) to modulate integrin-associated eosinophi
interactions with ASM cells can blunt the pro-remodeling
function of ASM cells in vitro. RGDS peptide is a non-selective
integrin receptor antagonists which mainly works through α4β1
integrin or αMβ2 integrin (Ahmadzai et al., 2015). These
integrins can recognize Ar-Gly-Asp amino acids motifs on
VCAM-1 or ECM proteins (Ruoslahti, 1996; Takagi, 2004).
Suppression of these integrins by RGDS peptide can block the
natural function of eosinophils to attach to airway structural
cells or ECM proteins after migration from peripheral blood.
We investigated the increased proliferation-promoting feature of
eosinophils from the asthma group with the aim of controlling
proliferation through blocking eosinophil attachment to the
surface of ASM cells.
MATERIALS AND METHODS
Subjects
Thirty-nine nonsmoking adults (men and women) were
included into the study: 22 patients with persistent mild to
moderate asthma defined according the GINA criteria and
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17 healthy subjects who comprised the control group. The
patients were recruited from the Department of Pulmonology
and Immunology, Hospital of the Lithuanian University of
Health Sciences, Kaunas. The study protocol was approved
by the Regional Biomedical Research Ethics Committee of
the Lithuanian University of Health Sciences (BE-2-13). Each
participant was informed about ongoing investigation and gave
his/her written consent.
Patients with asthma had a clinical history of the disease
for ≥1 year, current symptoms, airway hyperresponsiveness
and positive skin prick test (≥3mm) in response to house
dust mites Dermatophagoides pteronyssinus (D. pteronyssinus)
or Dermatophagoides farinae (D. farinae). All patients were not
using inhaled, nasal or oral steroids at least 1 month before visits,
short-acting β2 agonists at least 12 h and long-acting β2 agonists
at least 48 h prior the lung function test, antihistamines and
antileukotrienes—7 days before skin prick test and prior the lung
function test. None of the patients had a history of smoking.
Baseline forced expiratory volume in 1 s (FEV1) was more than
70% of the predicted value in all patients. All healthy subjects
were nonsmokers, without symptoms of rhinitis or asthma, with
normal findings of spirometry and methacholine challenge, and
all showed negative results of skin prick test. Demographic and
clinical data are presented in Table 1.
Lung Function Testing
Pulmonary function was tested using a pneumotachometric
spirometer “CustovitM” (Custo Med, Germany). Baseline forced
expiratory volume in 1 s (FEV1), forced vital capacity (FVC),
and FEV1/FVC ratio were recorded as the highest of three
reproducible measurements. The results were compared with the
predicted values matched for age, body height, and sex according
to the standard methodology.
Measurement of Airway Responsiveness
to Methacholine
Airway responsiveness was assessed as changes in airway
function after challenge with inhaled methacholine using a
TABLE 1 | Demographic, clinical and laboratory data of study subjects.
Characteristics Asthma
patients n = 22
Healthy
subjects n = 17
Age (years) 32.0 ± 1.9 27.7 ± 1.2
Gender (M/F), n 16/6 10/7
FEV1 (L) 3.71 ± 0.17 3.93 ± 0.19
FEV1 (% of predicted) 104.6 ± 2.55 101.1 ± 1.9
Wheal diameter induced by allergen (mm) 4.53 ± 1.4 0
PD20 (mg) 0.05
# NR
Blood eosinophil count (× 109/L) 0.32 ± 0.04* 0.14 ± 0.02
Sputum eosinophil count (× 109/L) 0.10 ± 0.02* 0.03 ± 0.004
F, female; M, male; FEV1, forced expiratory volume in 1 s; PD20, the provocation dose of
methacholine causing a 20% decrease in FEV1; NR, not responded. Data presented as
Mean ± standard error of the mean.*p < 0.01 comparing with healthy subjects peripheral
eosinophils count. #geometric mean.
reservoir method. Methacholine was nebulized into a 10-L
reservoir with a pressure nebulizer (Pari Provocation I; Pari,
Stanberg, Germany). Aerolized methacholine was inhaled
through a one-way valve at 5-min intervals starting with 15-µg
methacholine dose and doubling it until a 20% decrease in
FEV1 from the baseline or the total cumulative dose of 3.87mg
was achieved. The bronchoconstricting effect of each dose of
methacholine was expressed as a percentage of decrease in FEV1
from the baseline value. The provocative dose of methacholine
causing a ≥20% fall in FEV1 (PD20) was calculated from the log
dose-response curve by linear interpolation of two adjacent data
points.
Skin Prick Testing
All patients were screened for allergy by the skin prick test
using standardized allergen extracts (Stallergenes S.A., France)
for the following allergens: D. pteronyssinus, D. farinae, cat
and dog dandruff, 5 mixed grass pollen, birch pollen, mugwort,
Alternaria, Aspergillus, and Cladosporium. Temoin was used for
a negative control, and histamine hydrochloride (10mg/mL) was
used for a positive control. Skin testing was read 15 min after
application. The results of skin prick test were considered positive
if the mean wheal diameter was ≥3mm.
Sputum Induction, Processing, and Cells
Analysis
After baseline FEV1 and FVC measurements, subjects inhaled
10mL of sterile hypertonic saline solution (3, 4, or 5% NaCl,
Ivex Pharmaceuticals, USA) at room temperature. Nebulised
solution was given for three periods of 5 min at most by
an ultrasonic nebuliser ULTRA-NEBTM (DeVilbiss, USA). The
subjects were instructed to cough sputum into containers. If
any symptoms occurred, nebulisation was discontinued. It was
stopped after expectoration of an adequate amount of sputum.
In order to detect a possible decrease in FEV1, spirometry was
performed after each inhalation. Sputum was poured into a
Petri dish and separated from saliva. A 4-fold volume of freshly
prepared 0.1% dithiothreitol (DTT; Sigma-Aldrich) was added.
The mixture was vortexed and placed on ice and rocked on an
orbital shaker OS-10 (BIOSAN, Latvia) for 15 min. Next, an
equal volume of phosphate-buffered saline solution (PBS; Sigma-
Aldrich) was added to DTT. The cell pellet was separated using a
40-µm cell stainer (Becton Dickinson, USA). The mixture was
centrifuged for 10 min at 4◦C; the supernatant was aspirated
and stored at −70◦C for later analysis. The total cell counts,
percentage of epithelial cells, and cell viability were investigated
using a Neubauer hemocytometer (Heinz-Herenz, Germany)
under a microscope (BX43, OLYMPUS, USA) by employing
the Trypan blue exclusion method. The cytospin samples of
induced sputum were prepared using a cytofuge instrument
(Shandon Southern Instruments, USA). Supernatant with and
without DTTwas stored in 2mLmicrotubes at−70◦C for further
researches. The prepared sputum cytospins were stained by the
May-Grünwald-Giemsa method for differential cell counts. Cell
differentiation was determined by counting approximately 400
cells in random fields of view under a light microscope, excluding
squamous epithelial cells. The cells were identified by standard
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morphological criteria, nuclear morphology, and cytoplasmic
granulation.
Peripheral Blood Collection and Isolation
of Eosinophils
Peripheral blood samples for eosinophil isolation were collected
into sterile Vacutainer tubes with EDTA. Polymorphonuclear
leukocytes (PMN) were isolated by high-density gradient
centrifugation. The whole blood was layered on Ficoll-Paque
PLUS (GE Healthcare, Finland) and centrifuged at 1000 g force
for 30 min at room temperature, and then PMN were separated
by hypotonic lysis of erythrocytes. Eosinophils were separated
using a magnetic eosinophil isolation kit (Miltenyi Biotec, USA)
according to the procedure previously described (Januskevicius
et al., 2016). Manufacturer confirms that eosinophils separation
kit do not influence eosinophils viability and separation efficiency
are more than 97%. Eosinophils were counted using an ADAM
automatic cell counter (Witec AG, Switzerland)—eosinophils
viability must to be found at least 98%. To check eosinophil
purity after magnetic separation, a diluted eosinophil suspension
was fixed with methanol on a glass plate, stained with May–
Grunwald–Giemsa dyes, and inspected by light microscopy to
determine whether there was any other cell in the suspension.
ASM Cell Culture
Healthy human ASM cells, immortalized by stable expression
of hTERT, as described previously (Gosens et al., 2006), were
used for experiments. For all experiments, the same hTERT-
ASM cell line was used at Passage 5 for all 39 investigating
subjects, thus avoiding changes in ASM activity and viability
that could result from repeated thawing and passage. Cells
were cultivated in 75 cm2 Falcon culture flasks under standard
culture conditions of 5% CO2 in air at 37
◦C with medium
renewal every 2–3 days. For all experiments, passaged cells
were grown on plastic dishes in Dulbecco’s modified eagle
medium (DMEM) (GIBCO R©; Life Technologies, Paisley, UK)
supplemented with streptomycin/penicillin (2% v/v; GIBCO R©;
Life Technologies), amphotericin B (1% v/v; GIBCO R©; Life
Technologies), and fetal bovine serum (10% v/v; GIBCO R©;
Life Technologies). After reaching sufficient confluency, cells
were passaged by trypsinization. Cells were serum deprived in
DMEM supplemented with antibiotics and insulin, transferrin,
and selenium reagent (GIBCO R©; Life Technologies) before each
experiment to stop cell proliferation and avoid possible errors
in proliferation and gene expression measurements due to the
effects of mediators of bovine serum in growth medium.
Co-culture of ASM Cells and Eosinophils
Whole eosinophils were separated into 3 groups depended
by peptides were incubated with: control eosinophils—without
incubation with peptides; eosinophils incubated with integrins
blocking peptide RGDS; eosinophils incubated with integrins
non-blocking peptide (negative control) GRADSP. Respectively
amount of eosinophils suspension in serum-free growth medium
was taken and peptide solution was added to the final
concentration of 0.125 mg/ml. Eosinophils with peptides were
incubated for 1 h at 37◦C. After incubation eosinophils were
centrifuged, growth medium was removed and fresh serum-free
growth medium was added.
Cell cultivation dishes with approximately 2 × 105 ASM cells
were prepared and co-cultures was made by adding eosinophil
suspension with 0.5× 105 viable eosinophils to the ASM cells.
To observe and visualize cell growth, an inverted microscope
(CETI Inverso TC100; Medline Scientific, Oxford, UK) was used
which had a 10×/22 mm wide-field eyepiece, a phase objective of
10×/0.25, and an installed CETI Si-5C camera (Si-Cap software,
ver. 2.1, 2012).
Eosinophil Adhesion Assay
Airway smooth muscle (ASM) cells were seeded in six-well plates
(2 × 104 per well) and grown in DMEM//10% FBS for 3 days.
Medium was removed and wells were washed twice with warm
PBS. In serum-free DMEM (supplemented with 1% insulin-
transferrin-selenium reagent) cells were incubated for 1 day, after
which a co-culture with eosinophils was prepared.
Eosinophil adhesion was measured for up to 240min
thereafter, removing non-adherent cells by aspiration, then
washing cultures twice with warm PBS. Adherent eosinophil
abundance in the cultures was determined by measuring residual
eosinophil peroxidase (EPO) activity as previously described
(White et al., 1991). Because intercellular EPO levels may be
intrinsically lower in eosinophils from asthmatic individuals
owing to degranulation (Krug et al., 1999), increased EPO protein
levels detected by eosinophil adhesion assay in the co-culture
models can be assigned as a higher number of eosinophils stably
adhering to the ASM cell surface.
To assay EPO activity, 462µL DMEMwithout phenol red and
462 µL EPO substrate (1mM H2O2, 1mM o-phenylenediamine,
0.1% Triton X-100 in Tris buffer; pH 8.0) were added to each
well. After 30 min at 37◦C, 231 µL of 4M H2SO4 was added to
each well to stop the reaction and absorbance was measured at
490 nm using a microplate reader. Results are expressed relative
to substrate oxidation levels in control cells (ASM cells without
incubation with eosinophils). Light absorbance in control cell
wells is presented as 100% and eosinophil adhesion is expressed
as the difference from the control value.
Alamarblue® Proliferation Assay
Cells for proliferation measurements were grown in six-well
cluster plates in conditions described previously. Healthy ASM
cells were co-cultured with their respective eosinophil group
isolated from asthma patients and healthy individuals for 72 h.
Following co-culture, cells were washed once with warm PBS,
incubated for 4 min with warm PBS supplemented with 1 mM
EDTA to detach eosinophils from ASM cells, and washed again
with warm PBS to remove any remaining EDTA. Proliferation
was evaluated by incubating wells with Hank’s balanced salt
solution containing alamarBlue R© (10% v/v; InvitrogenTM; Life
Technologies, Paisley, UK). Conversion of alamarBlue R© to the
reduced form was dependent on the metabolic activity of ASM
cells and was assayed by dual-wavelength spectrophotometry
at wavelengths of 570 nm and 600 nm. As indicated by
the manufacturer, the degree of alamarBlue R© conversion is
proportional to the number of viable cells. Data are expressed as
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the percentage increase or decrease in alamarBlue R© conversion
by ASM cells compared with control cells (ASM cells cultured
without eosinophils), which did not proliferate during the
co-culturing period because of serum-free growth medium.
Detection of Protein Levels in Co-culture
Growth Medium
TGF-β1 and ECP protein levels in co-culture growth medium
were measured using ELISA according to the manufacturer’s
instructions. Twenty-four hours before experiments, growth
mediumwith fetal bovine serumwas changed to fresh serum-free
medium at the same volume for all wells. After a 24-h co-culture,
growth medium was collected in new 10mL tubes, centrifuged at
400 × g for 10 min at 25◦C to separate non-attached cells, and
2mL cryogenic tubes containing 1 mL supernatant were frozen
at −80◦C for protein level analysis. The results are expressed as
protein level per 1 mL growth medium. LDL for TGF-β1 is 23.44
pg/mL, for ECP–1.9 pg/ml.
RNA Isolation and Real-Time PCR
Total RNA was extracted using a miRNeasy mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. Real-
time PCR was performed using a Power SYBR R© Green RNA-
to-CT
TM 1-Step kit (Applied Biosystems, Foster City, CA) in a
7500 Fast Real-Time PCR system as follows: reverse transcription
at 48◦C for 30 min; activation of AmpliTaq Gold R© DNA
polymerase, UP (Ultra-Pure) at 95◦C for 10 min; 40 cycles
of denaturation at 95◦C for 15 s; and annealing and extension
at 60◦C for 1 min. Real-time PCR data were analyzed using
the comparative cycle threshold method (the amount of target
gene was normalized to the endogenous reference gene 18S
ribosomal RNA). A difference of 1 Ct (1Ct = 1, where Ct is the
amplification cycle number) after normalization to the reference
gene indicates a 2-fold higher expression level of the investigated
gene. Relative differences were determined by normalization of
test sample 1Cq values to control sample 1Cq values with the
equation 1Cq(control)−1Cq(test), and the differences in fold
were expressed by 211Ct value. Primers used to analyze gene
expression are shown in Table 2.
TABLE 2 | Sequences of primers used for gene expression analysis.
Primer Forward 5′-3′ Reverse 5′-3′
TGF-β1 GTACCTGAACCCGTGTTGCT GAACCCGTTGATGTCCACTT
Wnt-5a GGGTGGGAACCAAGAAAAAT TGGAACCTACCCATCCCATA
fibronectin TCGAGGAGGAAATTCCAATG ACACAGTGCACCTCATCAT
collagen
type Iα1
AGCCAGCAGATCGAGAACAT TCTTGTCCTTGGGGTTCTTG
α4 GCTTCTCAGATCTGCTCGTG GTCACTTCCAACGAGGTTTG
αM CAGACAGGAAGTAGCA
GCTCCT
CTGGTCATGTTGATGAA
GGTGCT
β1 GTGTGGCCCAAGACAGTTCT GGTTACCCCACCCTCTGACT
β2 CAACGTATGCGAGTGCCATTC TCACGGGGTTGTTCGACAG
18S CGCCGCTAGAGGTGAAATTC TTGGCAAATGCTTTCGCTC
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6
for Windows (ver. 6.05, 2014; GraphPad Software Inc., San
Diego, CA). Normally distributed data are mean and standard
error of the mean (SEM). Significant differences between two
independent groups were determined using the Mann–Whitney
U-test. The Wilcoxon matched-pairs signed rank test was used
for dependent groups. A p < 0.05 was considered statistically
significant.
RESULTS
Characteristics of the Studied Participants
The main characteristics of the study participants are shown
in Table 1. A total of 39 non-smoking adults participated in
the study (22 steroid-free patients with intermittent or mild-
to-moderate persistent asthma, and 17 healthy participants
who constituted the control group). There were no significant
differences in age, gender balance or FEV1 existed between
groups, however, the asthma group was unique in exhibiting
airway hyperresponsiveness (PD20) as well as skin prick
positivity. Notably, all asthma patients had significantly higher
numbers of peripheral blood eosinophils, and increased
eosinophil number in induced sputum (Table 1).
Eosinophil Integrin Expression and
Adhesion to ASM Cells
We observed that asthmatic eosinophils had 3.7 ± 1.0-fold
of α4, 4.6 ± 1.4-fold of αM, 4.1±1.1-fold of β1 and 16.8 ±
4.9-fold of β2 more mRNA, compared to eosinophils from
healthy individuals (Figure 1A). We also determined the effects
of eosinophil adhesion to cultured human ASM cells on the
abundance of α4, αM, β1, and β2 mRNA (Figure 1B). We
collected adherent asthmatic and healthy eosinophils after 24
h of co-culture with ASM cells, and determined that asthmatic
eosinophils exhibited a 6.0 ± 1.8-fold increase in α4 mRNA
compared to eosinophil that were not incubated with ASM cells
(p < 0.05). In striking contrast, eosinophils from healthy donors
exhibited no change in α4, β1, and β2 mRNA after 24 co-culture
with human ASM cells (Figure 1B). We measured no change in
other integrins subunits mRNA abundance after co-culture with
ASM cells in eosinophils from either healthy or asthmatic donors.
From the calibration curve, eosinophil number significantly
correlated with light absorbance value (Figure 2A). One hour
was the optimal period of incubation with RGDS peptide
(0.125mg/mL) for sufficient formation of the electrostatic
junction between the eosinophil integrin active center and
the amino acid peptides. Moreover, in pre-experiments, we
determined the most effective RGDS concentration that would
have a significant effect on suppressing eosinophil integrin and
determined that negative control GRADSP had no integrins
blocking properties as EPO substrate oxidation by non-treated
eosinophils and eosinophils incubated with GRADSP was equal
(Figure 2B).
For all eosinophil adhesion measurements, the same
eosinophil preparation protocol was used. This was a 1-h
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FIGURE 1 | Gene expression of eosinophil integrin. (A) Integrin gene expression differences between eosinophils isolated from asthmatic patients compared with
eosinophils from the healthy control group. (B) Influence of a 24-h incubation with airway smooth muscle (ASM) cells on gene expression of eosinophil integrin.
Results are mean ± SEM. Asthma group n = 22; control group n = 17. *p < 0.05 compared with healthy eosinophils; #p < 0.05 compared with control group
(eosinophils that had not been incubated with ASM cells).
FIGURE 2 | Measurement of eosinophil adhesion. (A) Calibration curve of eosinophil peroxidase (EPO) substrate oxidation dependency by eosinophil count.
(B) Eosinophil integrin-suppression efficiency at different Arg-Gly-Asp-Ser (RGDS)/Gly-Arg-Ala-Asp-Ser-Pro (GRADSP) concentrations. (C) Effects of blocking integrin
adhesion to airway smooth muscle (ASM) cells in the control group (healthy participants) at various periods of incubation. (D) Effects of blocking integrin adhesion to
ASM cells in the asthma group at various periods of incubation. Results are mean ± SEM. Asthma group n = 22; control group n = 17. Control: ASM cells that had
not been co-cultured with eosinophils; #p < 0.05 compared with eosinophils that had not been subject to integrin-blocking. Integrin-blocking: 1-h incubation with
RGDS/GRADSP in a 0.125 mg/mL final concentration.
incubation with 0.125mg/mL RGDS peptide or its negative
control, GRADSP.
Eosinophils isolated from the asthma group showed
significantly increased adhesion to ASM cells at all time points,
with an average value of 58.83 ± 4.50%. Integrin-blocking
peptide had a significant effect on reducing eosinophil adhesion
in both the control and asthma groups, with similar percentage
values. In the control group, adhesion decreased by an average of
9.54 ± 0.71% (Figure 2C), while blocking of eosinophil integrin
in the asthma group reduced adhesion by an average of 13.53 ±
2.70% (Figure 2D).
TGF-β1 Production
We investigated differences in eosinophil TGF-β1 gene
expression between the asthma group and the control group.
We found that the gene was expressed to a greater extent in the
asthma group (4.32 ± 0.68–fold) compared with the control
group (Figure 3A). Eosinophils from both groups were observed
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to induce TGF-β1 gene expression in ASM cells, but the effect
in the asthma group was significantly higher compared with the
control group (asthma group gene overexpression: 3.50 ± 0.44–
fold vs. control group gene overexpression: 2.26 ± 0.32–fold;
p< 0.05) (Figure 3B).
Considering that direct contact with ASM cells is necessary
to induce the effects of eosinophils, we investigated changes
in TGF-β1 gene expression after blocking eosinophil integrins.
Incubation with RGDS reduced the influence of eosinophils from
the control group from 2.26± 0.32–fold to 1.14± 0.34–fold, and
from 3.50 ± 0.44–fold to 2.08 ± 0.46–fold for the asthma group
(p < 0.05) compared with eosinophils incubated with GRADSP,
the negative control (Figure 3B).
Changes in gene expression had an influence on circulating
TGF-β1 protein levels in growth medium of co-cultures. With
ELISA of co-culture supernatant, we found that the highest
protein level was in medium from co-cultures of ASM cells and
eosinophils that were not subject to integrin-blocking from the
asthma group (270.9 ± 18.5 pg/mL). For the TGF-β1 level from
ASM cells cultivated alone under the same conditions, there was
an average difference of 162.7 pg per mL in the asthma group
compared with the control group. In the control group, TGF-
β1 levels were lower because there was less expression of this
growth factor gene in eosinophils and ASM cells after exposure
(the concentration in ASM cells cultivated alone was 78.1 ± 14.3
pg/mL, while in co-cultures of control eosinophils and ASM cells,
the protein level increased to 143.9 ± 29.1 pg/mL). Blocking
eosinophil integrins with RGDS peptide significantly reduced the
TGF-β1 level in growth medium of co-cultures of eosinophils
from the asthma group and ASM cells (reduced by 31 pg. per mL;
p < 0.05). In the control group, a reduction was also seen, but
because of too much variation in data, the p-value was over the
significance limit (Figure 3C).
Increase in TGF-β1 Production Was Not
Associated with the Level of Eosinophil
Cationic Protein (ECP)
As studies have reported that ECP stimulated TGF-β1 production
in lung fibroblasts (Zagai et al., 2007), we tested the hypothesis
that ECP released from eosinophils can induce overexpression of
TGF-β1 in ASM cells. To this end, we collected serum-free growth
medium from co-cultures of eosinophils and ASM cells and used
ELISA to estimate ECP protein levels.
The highest ECP protein level was observed in medium
from co-cultures of control eosinophils without integrin blocking
and ASM cells (1118.0 ± 132.4 pg/mL in eosinophils without
contact to exogenous proteins, and 1196.0 ± 140.7 in eosinophil
incubated with integrin non-binding peptide GRADSP). ECP
protein levels were significantly lower in medium containing
eosinophils from the asthma group (827.7 ± 118.3 pg per 1mL
in co-cultures with control eosinophils, and 865.2 ± 123.5 pg
per 1mL of growth medium in co-cultures with ASM cells
and eosinophils incubated with the negative control GRADSP).
Integrin-blocking peptide had a similar effect on reducing ECP
production in both the asthma and control groups. Blocking
eosinophil integrin in the control group showed a decrease in
ECP level of 271.6 pg per 1mL, whereas the asthma group
showed a decrease of 139.6 pg per mL compared with eosinophils
incubated with the negative control GRADSP (Figure 4).
Eosinophils Stimulated WNT-5a and ECM
Protein Production
We found that exposure to eosinophils from both the asthma
and control groups increased WNT-5a gene expression in ASM
cells, but the asthma group showed a significantly higher
effect (asthma group increase in gene expression of the ligand:
2.95 ± 0.46–fold vs. control group increase: 1.79 ± 0.16–
fold; p < 0.05). Reducing the ability of eosinophils to adhere
to the surface of ASM cells or ECM protein by integrin-
blocking using the RGDS peptide had a significant inhibitory
effect on WNT-5a gene expression. Decreased TGF-β1 levels
in co-cultures of ASM cells and asthma or control eosinophils
using integrin-blocking reduced WNT-5a gene expression,
and significant increases in expression were not observed
(Figure 5A).
We found that eosinophils from the asthma and control
groups showed an increase in fibronectin gene expression
in ASM cells by 3.51 ± 0.46–fold and 3.82 ± 0.41–fold,
respectively, without any significant differences between the
groups (Figure 5B). Eosinophils from the asthma group had a
significantly greater effect on type-1 collagen gene expression in
ASM cells compared with eosinophils from the control group
(eosinophils from the control group showed an increase in gene
expression of 3.47 ± 0.37–fold vs. the asthma group increase of
4.67± 0.53–fold; p< 0.05) (Figure 5C).
Eosinophil integrin-blocking had similar significant effects in
both groups. Fibronectin gene expression showed a reduction in
the asthma group to 2.50± 0.57–fold compared with the control
group which was 2.30 ± 0.24–fold. Importantly, suppression of
eosinophil integrin reduced the increased effect of eosinophils
on collagen gene expression (eosinophils from the control group
with integrin-blocking showed an increase in collagen gene
expression by 2.46 ± 0.31–fold vs. 2.81 ± 0.53–fold for the
asthma group) (Figures 5A,B).
Eosinophil-Induced ASM Cell Proliferation
Can Be Controlled by Eosinophil
Integrin-Blocking
Eosinophils isolated from peripheral blood of asthma patients
had a greater effect on ASM cell proliferation compared
with eosinophils from healthy control participants because
of increased adhesion ability. After eosinophils from the
asthma group were incubated for 72 h, we found that ASM
cells showed increased proliferation of 22.41 ± 3.78%,
whereas eosinophils from the control group only increased
by 6.90± 1.53%.
After ASM cells were incubated with eosinophils from the
asthma group and integrins were blocked, ASM cell proliferation
reduced to 11.52 ± 2.50%, while eosinophil integrin-blocking in
the control group showed that the proliferative effect was reduced
to 2.85± 0.82% (Figure 6).
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FIGURE 3 | Production of transforming growth factor-β1 (TGF-β1). (A) TGF-β1 gene expression differences between eosinophils isolated from asthmatic
patients compared with eosinophils from the healthy control group. (B) Changes in TGF-β1 gene expression in ASM cells after exposure to either eosinophils that had
or had not been subject to integrin-blocking. (C) Protein levels of free TGF-β1 in growth medium of eosinophil and ASM cell co-cultures. Results are mean ± SEM.
Asthma group n = 22; control group n = 17. #p < 0.05 compared with eosinophils that had not been subject to integrin-blocking; *p < 0.05 compared with
eosinophils from the control group. Control, ASM cells that had not been co-cultured with eosinophils; EOS control, non-treated eosinophils; integrin-blocking, 1-h
incubation with Arg-Gly-Asp-Ser (RGDS)/Gly-Arg-Ala-Asp-Ser-Pro (GRADSP) in a 0.125 mg/mL final concentration.
DISCUSSION
In this study we examined ASM remodeling in patients with
asthma and found that adhesion of eosinophils from steroid-
free asthma patients to ASM cells is important to induce ASM
cell proliferation after enhancing ECM protein production, and
that this effect can be controlled by the suppression of eosinophil
integrins. Eosinophils in asthma patients have significantly
increased activity compared with eosinophils in healthy people,
showing increased expression of outer-membrane integrins,
exhibiting overexpression of TGF-β1, having increased adhesive
properties, and having stronger effects on inducing gene
expression of TGF-β1, WNT-5a, and collagen in ASM cells.
These effects can be controlled using the small tetrapeptide
RGDS, which can non-specifically suppress eosinophil integrins
and reduce eosinophil adhesion, thereby influencing the ASM
remodeling process.
Airway smooth muscle (ASM) remodeling is associated with
varying levels of fibrosis, which is a result of increased deposition
and decreased degradation of ECM proteins (Araujo et al., 2008).
Both major symptoms of ASM remodeling (increased ASM
mass and ECM deposition) are closely related to chronic airway
inflammation and many authors correlate asthma severity with
eosinophil counts in the sputum or bronchoalveolar lavage fluid
(Bousquet et al., 1990; Loutsios et al., 2014).
While it is hard to manage eosinophil migration into the
airways, it may be possible to control eosinophil-induced
local inflammation. We hypothesized that one possible way to
influence the severity of asthma is by blocking eosinophil contact
with ASM cells or released ECM proteins.
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FIGURE 4 | Eosinophil cationic protein concentration in co-culture growth medium. Results are mean ± SEM. Asthma group n = 22; control group n = 17.
Negative control, ASM cells that had not been subject to co-culture with eosinophils; EOS control, non-treated eosinophils; integrin-blocking, 1-h incubation with
RGDS/GRADSP in a 0.125 mg/mL final concentration.
FIGURE 5 | Effect of eosinophil integrin-blocking on WNT-5a and extracellular matrix protein production in airway smooth muscle (ASM) cells. (A)
Influence of eosinophil integrin suppression on WNT-5a gene expression in ASM cells. (B) Influence of eosinophil integrin suppression on fibronectin gene expression
in ASM cells. (C) Influence of eosinophil integrin suppression on collagen gene expression in ASM cells. Results are mean ± SEM. Asthma group n = 22; control
group n = 17. Negative control, ASM cells that had not been subject to co-culture with eosinophils; EOS control, non-treated eosinophils: 1-h incubation with
Arg-Gly-Asp-Ser (RGDS)/Gly-Arg-Ala-Asp-Ser-Pro (GRADSP) in a 0.125 mg/mL final concentration. Statistical significance, p < 0.05.
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FIGURE 6 | Airway smooth muscle (ASM) cell proliferation after incubation with eosinophils. Results are mean ± SEM. Asthma group n = 22; control group
n = 17. Control, ASM cells that had not been subject to co-culture with eosinophils; integrin-blocking, 1-h incubation with Arg-Gly-Asp-Ser
(RGDS)/Gly-Arg-Ala-Asp-Ser-Pro (GRADSP) in a 0.125mg/mL final concentration. Statistical significance, p < 0.05.
By measuring eosinophils adhesion we noticed that blocking
of eosinophil integrins had similar effect on both, asthmatic and
healthy eosinophils groups and the low decrease in eosinophil
adhesion can be explained by different types of adhesion
properties, for example, cell–cell or cell–ECM protein contact.
However less affected eosinophils attachment may not reflect the
true integrin blocking effect concerning wide integrins functions.
Integrin adhesion can act as a signal transducer and can
control cell processes, such as cell growth, division, survival,
cellular differentiation, and apoptosis (Kim et al., 2011; Carbonell
et al., 2013). Different types of eosinophil integrins have different
roles in the control of cellular processes (Barthel et al., 2008;
Johansson, 2014), and blocking RGDS-binding integrins may
have a significant effect on ASM cell activity changes.
Increased asthmatic eosinophils adhesion could be explained
in part by our determined increased α4β1 and αMβ2 integrins
expression. α4β1 has been studied more extensively than any
other eosinophil integrin because of its role in mediating
adhesion (Barthel et al., 2006a) of purified blood or airway
eosinophils to VCAM-1 which is integrin counter-receptor
upregulated in the asthmatic lung. αMβ2 integrin is very useful
to investigate increased eosinophil adhesion because recognition
of αMβ2 is influenced greatly by activation with IL-5, which
enhances αMβ2-mediated static adhesion of blood eosinophils to
ICAM-1 or modules 1 or 4 of VCAM-1 (Sano et al., 2005; Barthel
et al., 2006b). This is important because there is a significant
increase in blood levels of IL-5 when eosinophils are activated
in vivo after their release from bone marrow (Joseph et al., 2004).
Eosinophils show increased TGF-β1 production, but are
not the only source of this growth factor in the lungs, there
are reports that ASM cells also produce this cytokine (Lee
et al., 2006; Januskevicius et al., 2016). How eosinophils induce
overexpression of TGF-β1 via ASM cells remains unknown.
Zagai with colleagues demonstrated that eosinophil cationic
protein released by eosinophil can promote TGF-β1 expression
by human lung fibroblasts after 2–48 h of incubation (Zagai et al.,
2007). To examine this possibility, we studied proteins levels of
ECP in co-cultures of growth medium containing eosinophils
and ASM cells after 24 h. The results are interesting as the
highest concentration of ECP protein was found in co-cultures of
eosinophils andASM cells from healthy control participants. This
findingmay be explained by degranulation of eosinophils isolated
from peripheral blood, which has less ECP protein in the granules
because. Under asthma conditions, a person has increased CCL
type cytokines concentration (Teran, 2000), which gives more
degranulation-promoting signals to eosinophils compared with
eosinophils from healthy people (Lintomen et al., 2008).
We found that blocking eosinophil adhesion with RGDS
peptide reduced eosinophil degranulation, evidenced by the
lower levels of ECP protein observed in co-culture growth
medium in both the asthma and control groups. It suggests an
idea that blocking of integrins can prevent ASM remodeling
by reducing eosinophils degranulation instead of acting only
as adhesion reducing agent. Moreover, reduced TGF-β1
concentration and significant differences between eosinophils
that were subject to integrin-blocking and eosinophils that were
not subject to integrin-blocking following a 24-h incubation
suggest that integrin suppression may be a potential method to
control eosinophil-induced TGF-β1 expression in ASM cells in
asthma.
One of latest findings suggests that there is crosstalk between
TGF-β1 and non-canonical Wnt signaling and associated ECM
protein deposition (Kumawat et al., 2013). Non-canonical Wnt
signaling activated via WNT-5a ligand is involved in adult
tissue homeostasis (Logan and Nusse, 2004; Clevers, 2006).
ASM remodeling is mainly characterized by increased muscle
mass because of cell hyperplasia and hypertrophy, but increased
production of specific types of ECM proteins is also an important
step in ASM abnormalities in asthma, as the ASM bundle
thickens and expresses more ECM and contractile proteins
compared with healthy people (Woodruff et al., 2004; Léguillette
et al., 2009; James et al., 2012). In the current study, we
sought to better understand and to control eosinophil-induced
ASM remodeling caused by altered ASM cell proliferation and
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ECM protein production. Eosinophil integrins were found to
be essential to induce the observed effects on WNT-5a gene
expression. After eosinophil integrin-blocking, WNT-5a gene
expression decreased to levels of no significance. Kumawat
et al. (2013) already showed that TGF-β1–Wnt signaling are
involved in release of fibronectin and collagen regulation. Our
results demonstrate ECM protein production by ASM cells
after exposure to eosinophils from asthma and control groups
in vitro. However, Halwani et al. (2013) suggested that ASM cells
proliferation increase irrespective of ECM proteins production in
asthma and presume that eosinophils enhance ASM proliferation
via the release of CysLTs.
TGF-β1 can induce the proliferation of structural cells,
and the joining of ASM cells with ECM protein can also
be recognized as a proliferation signal. Disturbing the stable
adhesion of eosinophils to ASM cells and the subsequent ECM
protein production cascade through eosinophil integrin-blocking
resulted in decreased eosinophil-induced ASM cell proliferation.
From measurements of ASM cell proliferation after exposure
to eosinophils, it was apparent that incubation of eosinophils
with RGDS peptide reduced the proliferative effect on ASM
cells by more than double compared with eosinophils that were
not subject to integrin-blocking. This result suggests the non-
specific binding of RGDS peptide to eosinophil integrin, which
partly reduces eosinophil adhesion, may significantly decrease
eosinophil activity by blocking the eosinophil integrin-activated
signaling cascade in ASM cells after binding to their receptors.
These findings are in agreement with previous findings by
Dekkers et al. (2010) who showed in animal model that RGDS
peptide inhibits ASM remodeling while eosinophil number was
not affected. These data together with our results about not high
impact to eosinophils adhesion suggest that the RGDS peptide
interferes with the way in which eosinophils adhere and signal to
ASM cells instead of highly affecting stable eosinophils adhesion.
Moreover, findings that adhesion of eosinophils are less affected
after integrins-blocking with RGDS peptide, but gene expression
levels of WNT-5a, TGF-β1, ECM proteins as well as cell number
aremore affected, suggest that cell-cell contact is less important in
the functional responses in ASM cells, whereas integrin signaling
and indirect action of eosinophils by released mediators may be
more important.
In our in vitromodel used eosinophils from peripheral blood,
which may result in differences when compared with the in vivo
situation, where eosinophils that have an effect on ASM cells
migrate from the peripheral blood into the airways and are called
airway tissue eosinophils (Liu et al., 1998). Despite that, it is
suggested that this model is reliable for use in in vitro studies
because eosinophils from people with asthma are known to be
primed or activated in vivo and to show enhanced responses to
different stimuli in vitro (Liu et al., 2003). Increased proportion
of eosinophils-ASM cells in vitro differs from in vivo context and
this may give elevated effects for all findings, however during
whole incubation period cultured ASM cells had contact only
with fixed number of eosinophils while in vivo ASM cells have
permanent contact with migrating eosinophils. Consequently the
study was designed to highlight the differences between effects of
asthmatic and healthy eosinophils on ASM cells. Moreover, most
of our results were based only on gene expression studies which
did not always reflect similar changes at the protein level.
CONCLUSIONS
The findings suggest that ASM remodeling can be controlled
by blocking the activity of eosinophil integrins thereby reducing
eosinophil adhesion to, and their effects on, ASM cells.
Suppression of eosinophil integrins may provide a potential
therapeutic tool to reduce eosinophilic inflammation associated
airway remodeling in asthma.
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